CN101511179A - Stat3的小分子抑制剂及其用途 - Google Patents

Stat3的小分子抑制剂及其用途 Download PDF

Info

Publication number
CN101511179A
CN101511179A CNA2006800123753A CN200680012375A CN101511179A CN 101511179 A CN101511179 A CN 101511179A CN A2006800123753 A CNA2006800123753 A CN A2006800123753A CN 200680012375 A CN200680012375 A CN 200680012375A CN 101511179 A CN101511179 A CN 101511179A
Authority
CN
China
Prior art keywords
cell
apoptosis
sta
stat3
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800123753A
Other languages
English (en)
Chinese (zh)
Inventor
H·宋
R·王
S·王
J·林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan Ann Arbor
Original Assignee
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan Ann Arbor filed Critical University of Michigan Ann Arbor
Publication of CN101511179A publication Critical patent/CN101511179A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2006800123753A 2005-02-25 2006-02-24 Stat3的小分子抑制剂及其用途 Pending CN101511179A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65659705P 2005-02-25 2005-02-25
US60/656,597 2005-02-25

Publications (1)

Publication Number Publication Date
CN101511179A true CN101511179A (zh) 2009-08-19

Family

ID=36928057

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800123753A Pending CN101511179A (zh) 2005-02-25 2006-02-24 Stat3的小分子抑制剂及其用途

Country Status (7)

Country Link
US (1) US20060247318A1 (enExample)
EP (1) EP1853242A4 (enExample)
JP (1) JP2008535785A (enExample)
CN (1) CN101511179A (enExample)
AU (1) AU2006216510A1 (enExample)
CA (1) CA2599393A1 (enExample)
WO (1) WO2006091837A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102961374A (zh) * 2012-12-12 2013-03-13 苏州大学 一种化合物的应用以及stat3抑制剂
CN104693280A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 信号传导及转录激活因子抑制多肽及其应用
CN104725480A (zh) * 2015-04-06 2015-06-24 苏州普罗达生物科技有限公司 一种信号传导及转录激活因子抑制多肽及其应用
CN106822898A (zh) * 2017-02-17 2017-06-13 南京九寿堂医药科技有限公司 靶向下调stat3基因表达在提高肺腺癌化疗敏感性方面的应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2625891A1 (en) 2005-10-14 2007-04-26 Carlton D. Donald Inhibition of pax2 by defb1 induction as a therapy for cancer
US7857804B2 (en) * 2006-09-01 2010-12-28 Mccaffrey Timothy A Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders
CA2671121C (en) * 2006-12-06 2016-06-07 University Of Central Florida Research Foundation, Inc. Stat3 inhibitor having anti-cancer activity and associated methods
CA2667364A1 (en) * 2007-01-16 2008-07-24 Musc Foundation For Research Development Compositions and methods for diagnosing, treating, and preventing prostate conditions
WO2009032338A1 (en) * 2007-09-09 2009-03-12 University Of Florida Research Foundation Apratoxin therapeutic agents: mechanism and methods of treatment
WO2009032351A1 (en) * 2007-09-09 2009-03-12 University Of Florida Research Foundation Natural product agents, derivatives, and methods of treatment
HRP20160949T1 (hr) 2007-09-10 2016-10-07 Boston Biomedical, Inc. Novi sastavi i metode za liječenje karcinoma
WO2009042677A2 (en) 2007-09-24 2009-04-02 Farjo Rafal A Stat3 inhibiting compositions and methods
US8450337B2 (en) 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
CA2793527A1 (en) 2010-03-19 2011-09-22 Boston Biomedical, Inc. Use of naphthofuran derivatives in the treatment of cancer
KR101273747B1 (ko) * 2010-09-09 2013-06-12 가톨릭대학교 산학협력단 Ｓｔａ-21을 유효성분으로 함유하는 관절염의 예방 및 치료용 조성물
WO2014169078A2 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
US11406707B2 (en) 2014-02-10 2022-08-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 phosphorylation during graft-versus-host disease
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
CN109988125B (zh) * 2018-10-25 2022-03-18 河南省锐达医药科技有限公司 一类新型苯甲酰苯胺化合物的制备方法和在肿瘤治疗上的应用
CN113939300A (zh) 2019-04-05 2022-01-14 凯麦拉医疗公司 Stat降解剂和其用途
WO2021232067A1 (en) * 2020-05-15 2021-11-18 Glg Pharma, Llc Stats3 inhibition for treatment and prevention of human coronavirus infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4491588A (en) * 1982-03-31 1985-01-01 University Of Tennessee Research Corporation Treatment of psoriasis and seborrheic dermatitis with imidazole antibiotics
WO2000044774A2 (en) * 1999-01-27 2000-08-03 The University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102961374A (zh) * 2012-12-12 2013-03-13 苏州大学 一种化合物的应用以及stat3抑制剂
CN102961374B (zh) * 2012-12-12 2015-01-14 苏州大学 一种化合物的应用以及stat3抑制剂
CN104693280A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 信号传导及转录激活因子抑制多肽及其应用
CN104725480A (zh) * 2015-04-06 2015-06-24 苏州普罗达生物科技有限公司 一种信号传导及转录激活因子抑制多肽及其应用
CN106822898A (zh) * 2017-02-17 2017-06-13 南京九寿堂医药科技有限公司 靶向下调stat3基因表达在提高肺腺癌化疗敏感性方面的应用

Also Published As

Publication number Publication date
CA2599393A1 (en) 2006-08-31
WO2006091837A3 (en) 2009-04-16
WO2006091837A2 (en) 2006-08-31
JP2008535785A (ja) 2008-09-04
EP1853242A2 (en) 2007-11-14
US20060247318A1 (en) 2006-11-02
AU2006216510A1 (en) 2006-08-31
EP1853242A4 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
CN101511179A (zh) Stat3的小分子抑制剂及其用途
Mondini et al. Radiotherapy–immunotherapy combinations–perspectives and challenges
Peng et al. Altered glycolysis results in drug-resistant in clinical tumor therapy
US7432304B2 (en) Small molecule antagonists of Bcl-2 family proteins
CN1960719B (zh) 棉酚共结晶及其应用
CN104884065B (zh) 治疗癌症的方法
ES2643233T3 (es) Miméticos de SMAC bicíclicos diazo bivalentes y los usos de los mismos
ES2657649T3 (es) Inhibidores de Mcl-1 de molécula pequeña y sus usos
CN101132783B (zh) 阿朴棉子酚酮及其用途
US11510872B2 (en) Nanoparticle-lipid composite carriers and uses thereof
Abuzaid et al. Apoferritin-encapsulated Jerantinine A for transferrin receptor targeting and enhanced selectivity in breast cancer therapy
US20090175869A1 (en) Pulsatile Dosing of Gossypol for Treatment of Disease
Pan et al. Anti-CLL1 liposome loaded with miR-497-5p and venetoclax as a novel therapeutic strategy in acute myeloid leukemia
Li et al. Radioiodine-labeled anti-epidermal growth factor receptor binding bovine serum albumin-polycaprolactone for targeting imaging of glioblastoma
Li et al. Cucurbitacin IIa promotes the immunogenic cell death‑inducing effect of doxorubicin and modulates immune microenvironment in liver cancer
US7910621B2 (en) Small molecule antagonists of XIAP family proteins
US20200129586A1 (en) Compositions and methods for treating conditions related to adrenocortical activity and/or excessive steroid production
WO2020151727A1 (zh) 药物复合物及其制备方法和用途
Vien et al. A New Liposomal Formulation of Hydrogenated Anacardic Acid to Improve Activities Against Cancer Stem Cells
US10117908B2 (en) Suppression of cellular transformation and dysplasia by topical application of lefty
JP2021505691A (ja) 新規キノカルコン化合物、及びがん又は炎症を治療するためのその用途
Yu et al. The Radiosensitizing Effect of Tumor-Derived Microparticles Co-Loaded with Sorafenib and Gold Nanoparticles on Hepatocellular Carcinoma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090819